Log in

NRSN NeuroSense Therapeutics Ltd. NASDAQ · Israel

NeuroSense Therapeutics (NRSN) news

Top story · Oct 2, 2026 · Company press release

NeuroSense Provides Update on Nasdaq Listing Compliance

Company regains compliance with Nasdaq’s minimum bid price requirement and intends to request a Nasdaq Hearings Panel hearing to seek additional time to regain compliance with the minimum market value requirement

Source: 6-K filed Oct 2, 2026 on SEC EDGAR

Latest NeuroSense Therapeutics news

We have not published a story on NeuroSense Therapeutics yet. When there is news, it will appear here.

NeuroSense Therapeutics annual financials

LineFY2025FY2024
Research and development$6.2 million$5.7 million
Net income (loss)-$11.1 million-$10.2 million
Cash from operations-$7.7 million-$10.1 million
Cash and equivalents$166,000$3.4 million

Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $166,000.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about NeuroSense Therapeutics

What is the ticker symbol of NeuroSense Therapeutics?

NeuroSense Therapeutics Ltd. trades under the ticker NRSN on NASDAQ.

Where is NeuroSense Therapeutics listed?

NeuroSense Therapeutics Ltd. is listed on NASDAQ.

What is the SEC CIK of NeuroSense Therapeutics?

The SEC Central Index Key (CIK) for NeuroSense Therapeutics Ltd. is 1875091. Its filings are on SEC EDGAR.

How many shares does NeuroSense Therapeutics have outstanding?

32,557,174 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-31.

Which country or territory is NeuroSense Therapeutics listed under?

Our directory records NeuroSense Therapeutics Ltd. under Israel.

What does NeuroSense Therapeutics do?

Our directory classifies NeuroSense Therapeutics Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of NeuroSense Therapeutics?

The ISIN recorded for NeuroSense Therapeutics Ltd. is IL0011809592.

Does aibio.space cover NeuroSense Therapeutics?

aibio.space lists NeuroSense Therapeutics Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is NeuroSense Therapeutics incorporated?

SEC records list its state or country of incorporation as L3.

Is NeuroSense Therapeutics profitable?

NeuroSense Therapeutics Ltd. reported a net loss of $11.1 million for the fiscal year ended Dec 31, 2025, and used $7.7 million of cash in operations, per its annual report to the SEC.

How much does NeuroSense Therapeutics spend on research and development?

$6.2 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does NeuroSense Therapeutics have?

$166,000 in cash at Dec 31, 2025, per its 20-F.

Is NeuroSense Therapeutics a smaller reporting company?

SEC records list NeuroSense Therapeutics Ltd.'s filer category as: Non-accelerated filer<br>Emerging growth company.

Where is NeuroSense Therapeutics headquartered?

SEC records list its business address as 11 HAMENOFIM ST., HERZLIYA, Israel, 4672562.

When does NeuroSense Therapeutics's fiscal year end?

NeuroSense Therapeutics Ltd.'s fiscal year ends on December 31, per SEC records.

Investor discussion: NeuroSense Therapeutics

Members talk about NeuroSense Therapeutics (NRSN). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at NeuroSense Therapeutics, newest first. Each line links the filing it comes from.

  1. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source

  2. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source

  3. Listings

    Reported a reverse stock split. SEC Form 6-K. Source

  4. Listings

    Reported a reverse stock split. SEC Form 6-K. Source

  5. Listings

    Reported a reverse stock split. SEC Form 6-K. Source

  6. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source

  7. Listings

    Reported a reverse stock split. SEC Form 6-K. Source

  8. Financings

    Reported a financing. SEC Form 6-K. Source

  9. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source

  10. Financings

    Set up an at-the-market program to sell shares over time. SEC Form F-3. Source

  11. Financings

    Reported a financing. SEC Form 6-K. Source

  12. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source

  13. Financings

    Set up an at-the-market program to sell shares over time. SEC Form F-3. Source

  14. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source

  15. Financings

    Reported a financing. SEC Form 6-K. Source

  16. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:NRSN on TradingView.

SEC filings and registration

SEC name
NeuroSense Therapeutics Ltd.
CIK
1875091
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
NRSN (Nasdaq), NRSNW (Nasdaq)
State or country of incorporation
L3
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Emerging growth company
Business address
11 HAMENOFIM ST., HERZLIYA, Israel, 4672562
Phone
972-9-9531142
Shares outstanding
32,557,174 as of 2025-12-31 (20-F filed 2026-03-31)

Recent filings (8-K and 6-K are the company's own announcements)

  • 6-K filed 2026-10-19
  • 6-K filed 2026-10-13
  • 6-K filed 2026-10-02
  • 6-K filed 2026-09-25
  • 6-K filed 2026-09-09
  • 6-K filed 2026-08-27
  • 6-K filed 2026-08-13
  • 6-K filed 2026-08-06

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

NeuroSense Therapeutics Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NRSN, recorded under Israel. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
NeuroSense Therapeutics Ltd.
Ticker
NRSN
Listing
NASDAQ
Country or territory
Israel
Business scope
Pharmaceuticals: Major
ISIN
IL0011809592
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.